Hannah M. Lee

ORCID: 0000-0003-0764-9737
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Liver Disease Diagnosis and Treatment
  • Hepatitis B Virus Studies
  • Hepatitis C virus research
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Liver Disease and Transplantation
  • Alcohol Consumption and Health Effects
  • Liver Diseases and Immunity
  • Organ Transplantation Techniques and Outcomes
  • Pancreatic and Hepatic Oncology Research
  • Gut microbiota and health
  • Cholangiocarcinoma and Gallbladder Cancer Studies
  • Oropharyngeal Anatomy and Pathologies
  • Protein Degradation and Inhibitors
  • Hepatitis Viruses Studies and Epidemiology
  • Cancer survivorship and care
  • Pediatric Hepatobiliary Diseases and Treatments
  • Child and Animal Learning Development
  • Sleep and Work-Related Fatigue
  • Older Adults Driving Studies
  • Liver physiology and pathology
  • Salmonella and Campylobacter epidemiology
  • Vibrio bacteria research studies
  • Migration, Health and Trauma
  • Cancer Mechanisms and Therapy
  • Education and Learning Interventions

Virginia Commonwealth University Medical Center
2018-2025

Hunter Holmes McGuire VA Medical Center
2022-2025

Virginia Commonwealth University
2016-2024

University of California, San Diego
2023

Directorate-General for Interpretation
2016

Tufts University
2012-2015

Tufts Medical Center
2006-2014

Representatives from academia, industry, regulatory agencies, and patient advocacy groups convened under the American Association for Study of Liver Diseases (AASLD) European (EASL) in June 2022 with primary goal achieving consensus on chronic HBV HDV treatment endpoints to guide clinical trials aiming “cure” HDV. Conference participants reached an agreement some key points. The preferred endpoint phase II/III evaluating finite treatments hepatitis B (CHB) is a “functional” cure, defined as...

10.1097/hep.0000000000000431 article EN Hepatology 2023-06-16

The management of chronic hepatitis B (CHB) during pregnancy remains a challenge and involves various aspects maternal–fetal care. Despite the standard immunoprophylaxis, significant portion infants born to highly viremic mothers remain infected with virus (HBV). Emerging data suggest that antiviral therapy in third trimester can prevent immunoprophylaxis failure. To minimize fetal exposure agents, should be reserved for advanced disease or who are at risk hepatic decompensation. Current...

10.1055/s-0033-1345718 article EN Seminars in Liver Disease 2013-06-08

Abstract Background & Aims Non‐alcoholic fatty liver disease (NAFLD) affects about 25% of the general population worldwide. Although epidemiology NAFLD is well studied in United States, there paucity data for Asian Americans. Our aim was to assess prevalence and risk factors among Methods We utilized NHANES 2011‐2016. defined using recently derived US‐FLI. Relative risks (RRs) attributable fractions (PAFs) metabolic components on atherosclerotic cardiovascular (ASCVD) advanced fibrosis...

10.1111/liv.14038 article EN Liver International 2018-12-31

OBJECTIVES: Data from the United States are lacking regarding impact of entecavir (ETV) on risk hepatocellular carcinoma (HCC). Our aim is to determine whether treatment with ETV associated a reduced HCC by calculating expected incidence based Risk Estimation for Hepatocellular Carcinoma in Chronic Hepatitis B (REACH-B) model and comparing it observed incidence. METHODS: The US patients treated between 2005 2013 retrospective cohort was obtained. predicted calculated using REACH-B model....

10.1038/ajg.2016.257 article EN The American Journal of Gastroenterology 2016-06-22

Preclinical data suggest histone deacetylase inhibitors improve the therapeutic index of sorafenib. A phase I study was initiated to establish recommended 2 dose sorafenib combined with vorinostat in patients unresectable hepatocellular carcinoma.Patients received (200 400 mg by mouth once daily, 5 7 d) and at standard or reduced doses (400 [cohort A] 200 B] twice daily). Patients who 14 days cycle 1 were evaluable for dose-limiting toxicity (DLT).Sixteen treated. Thirteen response. Three...

10.1097/coc.0000000000000567 article EN American Journal of Clinical Oncology 2019-07-12

Background This study’s aim was to show the feasibility and safety of robotic liver resection (RLR) even without extensive experience in major laparoscopic (LLR). Methods A single center, retrospective analysis performed for consecutive resections solid tumors from 2014 2022. Results The included 226 resections, comprising 127 (56.2%) open surgeries, 28 (12.4%) LLR, 71 (31.4%) RLR. rate RLR increased that LLR decreased over time. In a comparison between propensity score matching-selected...

10.1177/00031348241259043 article EN The American Surgeon 2024-06-05

Yttrium-90 (Y90) radioembolization is a catheter-based therapy for hepatocellular carcinoma (HCC). Multiple trials have evaluated the efficacy of Y90 in HCC; however, few assessed long-term hepatic function. This study aimed to evaluate clinical real-world experience effectiveness and impact on function.A single-center retrospective chart review was performed patients with Child-Pugh (CP) class A or B who received primary HCC between 2008 2016. Model end-stage liver disease (MELD) CP scores...

10.21037/jgo-22-882 article EN Journal of Gastrointestinal Oncology 2023-05-12

Cognitive dysfunction due to minimal hepatic encephalopathy (MHE) adversely impacts patients with cirrhosis and more precise therapies are needed. Gut-brain axis changes therapeutic targets, but prior studies have largely focused on bacterial changes. Our aim was determine linkages between individual cognitive testing results bacteria the virome using a cross-sectional longitudinal approach. We included (n = 138) analyses 36) of tested three modalities, which were psychometric score (PHES),...

10.1080/19490976.2023.2288168 article EN cc-by Gut Microbes 2023-11-27

Hepatocellular carcinoma (HCC) is a challenging malignancy with limited treatment options beyond surgery and chemotherapy. Recent advancements in targeted therapies immunotherapy, including PD-1 PD-L1 monoclonal antibodies, have shown promise, but their efficacy has not met expectations. Biomarker testing personalized medicine based on genetic mutations other biomarkers represent the future direction for HCC treatment. To address these challenges opportunities, this comprehensive review...

10.3389/fimmu.2023.1285370 article EN cc-by Frontiers in Immunology 2023-12-19

Hepatoma Research is an open access journal and focuses on all topics related to hepatoma. The following articles are especially welcome: pathogenesis, clinical examination early diagnosis of hepatoma, complications their preventions treatments, etc.

10.20517/2394-5079.2021.07 article EN Hepatoma Research 2021-01-01

As the third most common cause of cancer‐related death worldwide with significant mortality rates in United States, hepatocellular carcinoma has strong association cirrhosis and chronic hepatitis B virus (HBV) a growing at‐risk population from rise liver disease alcohol use nonalcoholic fatty disease. Despite this, progress identifying individuals early detection HCC these populations have lagged behind treatment advances.The lack consensus may undermine widespread adoption surveillance...

10.1002/hep.32741 article EN cc-by-nc-nd Hepatology 2022-08-22

Abstract Background and Aims Gut microbiota, including bacteria phages, are altered in cirrhosis, but their role during infections spontaneous bacterial peritonitis (SBP) prophylaxis is unclear. Our aim was determine metagenomic changes gut bacteria; phages linkages centered around Gram‐negative Gram‐positive pathobionts patients with cirrhosis with/without or SBP prophylaxis. Approach Results We included uninfected ( n = 231) infected 30, 19 urinary tract infection 11 before antibiotics)...

10.1002/hep.32571 article EN Hepatology 2022-05-13

Hepatoma Research is an open access journal and focuses on all topics related to hepatoma. The following articles are especially welcome: pathogenesis, clinical examination early diagnosis of hepatoma, complications their preventions treatments, etc.

10.20517/2394-5079.2020.113 article EN Hepatoma Research 2021-01-07

Abstract Driving is independently affected by cirrhosis and hepatic encephalopathy (HE) alcohol/substance use, but their concomitant impact unclear. We aimed to determine the of alcohol other substances on driving‐simulator performance in with without HE. Outpatients controls underwent cognitive testing driving simulation for following three conditions: baseline, wearing goggles simulating intoxication, opioid/benzodiazepine abuse. Outcomes were number centerline crossings (CCs) road‐edge...

10.1002/hep4.2028 article EN cc-by-nc-nd Hepatology Communications 2022-07-17

Background: Conflicts, natural disasters, and persecution have led to growing refugee populations worldwide. Vision impairment within these is a significant concern. Eye conditions in children appear peak during times of resettlement. Future medical nursing professionals need be trained detect treatable that could lead permanent vision loss morbidity if undiagnosed. While curricula regarding health exist, no curriculum exists on identifying common eye performing pediatric screening. Methods:...

10.62694/efh.2024.65 article EN Education for Health 2024-09-08
Coming Soon ...